Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF 100 Intrinsic Value: Projected FCF is $5.21 as of Aug. 22, 2026, which is 93% above its 10-year median of 2.70. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.08 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 628 Drug Manufacturers companies, BioGaia AB ranks worse than 66.72% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-22), BioGaia AB's Intrinsic Value: Projected FCF is $5.21. The stock price of BioGaia AB is $11.55. Therefore, BioGaia AB's Price-to-Intrinsic-Value-Projected-FCF of today is 2.2.
The historical rank and industry rank for BioGaia AB's Intrinsic Value: Projected FCF or its related term are showing as below:
BGLAF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2 Med: 2.7 Max: 4.17
Current: 2.22
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of BioGaia AB was 4.17. The lowest was 2.00. And the median was 2.70.
BGLAF's Price-to-Projected-FCF is ranked worse than 66.72% of 628
companies
in the Drug Manufacturers industry
Industry Median: 1.59
vs BGLAF: 2.22
BioGaia AB (OTCPK:BGLAF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
BioGaia AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
11.55
/
5.1300361999558
=
2.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB Intrinsic Value: Projected FCF Related Terms
BioGaia AB Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLAF vs ZTS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Price-to-Projected-FCF falls into.
BioGaia AB Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $5.21 mean?
BioGaia AB (BGLAF) has a Intrinsic Value: Projected FCF of $5.21 as of Aug. 22, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BioGaia AB and its competitors. This is 93% above median its historical median of 2.70. Over the past decade, BioGaia AB's Intrinsic Value: Projected FCF has ranged from 2.00 to 4.17. According to the industry distribution chart, BioGaia AB ranks #419 out of 628 companies in the Drug Manufacturers industry, placing it in the top 66.7%.
Is BioGaia AB's Intrinsic Value: Projected FCF too high?
BioGaia AB's current Intrinsic Value: Projected FCF of $5.21 is 93% above median its 10-year median of 2.70. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.17. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.59. BioGaia AB's value of $5.21 is 227.7% above this industry median. Based on the distribution chart, BioGaia AB ranks #419 out of 628 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Intrinsic Value: Projected FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #419 out of 628 companies for Intrinsic Value: Projected FCF. This places BioGaia AB in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.59. BioGaia AB's value of $5.21 is 227.7% above this benchmark. Historically, BioGaia AB's own Intrinsic Value: Projected FCF has ranged from 2.00 to 4.17 over the past decade. While the company's 10-year median is 2.70 vs. the industry median of 1.59, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.59, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Intrinsic Value: Projected FCF of $5.21 is 227.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Intrinsic Value: Projected FCF is $5.21, which is 93% above median its own 10-year median of 2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.08, compared to a current price of $11.55 — trading 11.7% below its estimated fair value. The current Intrinsic Value: Projected FCF is $5.21, which is 93% above median its 10-year median of 2.70 and 227.7% above the Drug Manufacturers industry median of 1.59. BioGaia AB's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Intrinsic Value: Projected FCF is $5.21 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $11.55 is trading 11.7% below its estimated GF Value™ of $13.08.
GuruFocus considers BioGaia AB to be Modestly Undervalued.
Key valuation signals for BGLAF:
Intrinsic Value: Projected FCF: $5.21 (93% above median its 10-year median of 2.70)
GF Value™: $13.08 vs. price of $11.55 (11.7% below fair value)
Industry Position: 227.7% above the Drug Manufacturers median (#419 of 628)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
